Cell Biosciences Accelerates Transition to Commercial Entity, Plans to Buy Alpha Innotech for $20M | GenomeWeb

This story originally ran on Sept. 15.

Cell Biosciences last week announced it had entered into a definitive agreement to acquire Alpha Innotech for $20 million in a deal that further accelerates Cell Biosciences' transition to a full commercial operation.

Under the terms of the deal, anticipated to close in 60 days, Cell Biosciences would pay $1.50 for each share of Alpha Innotech stock for a total of $17.9 million in cash. It also would assume $2.1 million of outstanding debt from Alpha Innotech.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.